InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,469.30
(
0.00%
)
US TECH 100
19,121.60
(
-0.28%
)
Dow Jones
39,112.16
(
0.00%
)
Brent Oil
84.42
(
0.27%
)
Bitcoin
61,455.15
(
-0.58%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

jaybe

Send PM Follow Ignore
Followers 5
Posts 277
Boards Moderated 0
Alias Born 05/29/2011

jaybe

Re: None

Friday, 07/19/2013 4:22:01 PM

Friday, July 19, 2013 4:22:01 PM

Post# of 80490
Novartis cancels PH3 Dovitinib vs. Sorafenib...

"...drug did not meet its primary endpoint of progression-free survival compared to sorafenib in patients with metastatic renal cell carcinoma (mRCC) after failure with prior therapies."

Supposedly a trial in VEGFR TKI resistant patients, but as you can see below Dovi should be competitive with Sora. This could still be the case and the trial was stopped due to safety concern that Novartis will never disclose.

Dovitinib inhibits FGFR, PDGFR, VEGF, cKIT, FLT3, CSFR1, Trk and RET similar to Pona's hit list, but at much higher IC50 values.

Compare IC50: FGFR1 /FGFR2 / FGFR3 / FGFR3 / VEGFR2
Ponatinib 2 / 2 / 18 / 8 / 1.5
Dovitinib 13 / 21 / 18 / 470 / 5.4
Sorafenib 64 / 825 / 1019 / - / 28


http://www.fiercebiotech.com/story/novartis-buries-phiii-kidney-cancer-failure-behind-q2-successes/2013-07-19
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up